VIENNA, June 19 (Reuters) - Austria’s Intercell ICEL.VI has submitted its vaccine against Japanese encephalitis for approval in Canada, the company said in Thursday.
The product has already been submitted for approval in the United States, Europe and Australia, and Intercell said approval procedures as well as its manufacturing operations were going according to plan.
With over 3 billion people living in endemic areas, mosquito-borne Japanese encephalitis is the leading cause of childhood encephalitis and viral encephalitis in Asia.
Switzerland’s Novartis AG NOVN.VX has a marketing and distribution agreement for the vaccine in the U.S., Europe and some other markets in Asia and Latin America with Intercell. (Reporting by Karin Strohecker, editing by Will Waterman)